UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

AN2 Therapeutics

AN2 Therapeutics logo

AN2 Therapeutics

BiotechnologyUnited States
Visit WebsiteContact Company

About AN2 Therapeutics

Grounded in a proprietary boron chemistry platform, AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate.

The development pipeline spans haematologic diseases, infectious diseases and oncology, with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines.

AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases, particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry.

Further information is available at an2therapeutics.com.

Areas of Expertise

Clinical-stage DevelopmentHaematologyInfectious DiseaseOncologySmall-molecule Drug Discovery

Services & Capabilities

Clinical-stage DevelopmentHaematologyInfectious DiseaseOncologySmall-molecule Drug Discovery
Similar Companies

More in Biotechnology

A

Actimed Therapeutics

Focused exclusively on the treatment of muscle wasting disorders, Actimed Therapeutics is advancing a pipeline of novel compounds targeting cancer-related cachexia and related conditions for which no globally approved pharmaceutical treatment currently exists. The clinical-stage biotechnology company aims to transform care for a patient population that has historically been under-served, with a stated goal of prolonging and improving quality of life, restoring dignity, and easing the burden on patients, carers, and healthcare providers alike. Cancer-related cachexia is a progressive wasting syndrome that accompanies cancer and other serious chronic illnesses. It is associated with significant morbidity and mortality, yet despite its prevalence and devastating clinical impact, therapeutic options remain very limited. Actimed Therapeutics has positioned itself at the frontier of this unmet medical need. The company's pipeline centres on two investigational agents: S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002), both of which are being explored in the context of cachexia, cancer cachexia, muscle optimisation in obesity, and amyotrophic lateral sclerosis. The dual-compound approach reflects a broadening scientific focus on anabolic and anti-catabolic mechanisms in muscle biology. Governance includes a board, management team, founders, and an advisory panel, indicating an organised leadership structure appropriate to a company at this stage of development. Actimed Therapeutics operates with a clear patient-centred mission, directing its research towards conditions where conventional medicine has yet to deliver a definitive solution. Further information is available at actimedtherapeutics.com.

View profile
A

Adcentrx Therapeutics

Founded in 2021 and headquartered in San Diego, California, Adcentrx Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer and other life-threatening diseases. The company's work centres on its proprietary i-Conjugation platform, which addresses the principal engineering challenges of ADC design, including stable conjugation chemistry, cleavable linker technology, and controlled drug-antibody ratio (DAR 8), to maximise payload delivery to solid tumour cells while limiting systemic toxicity. Clinical Pipeline Adcentrx has advanced two candidates into Phase 1a/b clinical trials. ADRX-0706 is a Nectin-4 ADC currently in Phase 1b evaluation across a range of advanced solid tumours; the US FDA has granted it Fast Track Designation for locally advanced or metastatic squamous cell cervical cancer. ADRX-0405 is a STEAP1-targeting ADC in Phase 1a evaluation for metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer; it carries FDA Orphan Drug Designation for gastric cancer and is regarded as a potential first-in-class candidate for its target. Both programmes build on the i-Conjugation platform's aim to deliver best-in-class or first-in-class ADCs with differentiated clinical profiles. Funding & Partnerships Adcentrx has raised approximately $101 million across three financing rounds, including a Series A+ of $51 million led by Eight Roads Ventures and extended with participation from Quan Capital and Partners Investment. The company has entered a multi-target antibody discovery collaboration with AvantGen to source novel antibody candidates for its ADC pipeline. Further information is available at adcentrx.com.

View profile
A

Alkahest

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy